Q: Could you comment on ATS earnings, please.
5i Research Answer:
EPS was 65c vs estimates of 56c; revenue of $791.5M beat estimates of $722M. EBITDA of $115.8M beat estimates by ~7%. Revenue rose 8%, income rose about 50%. Life sciences revenue grew 16%. Order bookings were 7.3% higher at $791M, bringing backlog to $1.79B. Total backlog is still lower than last year, but the booking strength is an improvement from last quarter. We are comfortable with these numbers and they should take a bit of pressure off of the stock.